Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab

Gynecologic Oncology

Volumn 120, Issue 2, 2011, Pages 313-314

  Bansal, Nisha ^a   Hoffman, Mitchell ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Bevacizumab; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CALCIUM; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; PACLITAXEL; TOPOTECAN;

ABDOMINAL PAIN; ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; BLADDER PERFORATION; BLADDER TUMOR; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CONTRAST MEDIUM EXTRAVASATION; DIARRHEA; DISEASE COURSE; DRUG WITHDRAWAL; DYSURIA; EPITHELIUM CELL; FEMALE; HEMATURIA; HUMAN; LIVER INJURY; METASTASIS; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; RECURRENT CANCER; SHORT SURVEY; SIDE EFFECT;

EID: 79251599069     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.10.002     Document Type: Article

References (4)

1. L.M. Randall, and B.J. Monk Bevacizumab toxicities and their management in ovarian cancer Gynecol Oncol 117 2010 497 504
2. J.P. Diaz, W.P. Tew, and O. Zivanovic Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma Gynecol Oncol 116 2010 335 339
3. S.A. Cannistra, U.A. Matulonis, and R.T. Penson Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 33 2007 5180 5186
4. J.D. Wright, A.A. Secord, and T.M. Numnum A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer Int J Gynecol Cancer 18 3 2008 400 406